Total Payments
$530.53
2024 Payments
$18.09
Companies
13
Transactions
18
Medicare Patients
26,707
Medicare Billing
$22.7M
Payment Breakdown by Category
Food & Beverage$312.26 (58.9%)
Education$184.57 (34.8%)
Gifts$33.70 (6.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $312.26 | 10 | 58.9% |
| Education | $184.57 | 7 | 34.8% |
| Gift | $33.70 | 1 | 6.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Sirtex Medical Inc | $122.98 | 1 | $0 (2019) |
| Astellas Pharma US Inc | $98.95 | 1 | $0 (2020) |
| Elekta, Inc. | $91.36 | 1 | $0 (2019) |
| PFIZER INC. | $50.24 | 4 | $0 (2023) |
| Merck Sharp & Dohme LLC | $42.60 | 3 | $0 (2024) |
| Welch Allyn | $33.70 | 1 | $0 (2020) |
| Celgene Corporation | $18.58 | 1 | $0 (2017) |
| E.R. Squibb & Sons, L.L.C. | $17.33 | 1 | $0 (2020) |
| Karyopharm Therapeutics Inc. | $12.45 | 1 | $0 (2020) |
| Acrotech Biopharma LLC | $11.97 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $18.09 | 1 | Merck Sharp & Dohme LLC ($18.09) |
| 2023 | $13.86 | 1 | PFIZER INC. ($13.86) |
| 2021 | $23.89 | 2 | Acrotech Biopharma LLC ($11.97) |
| 2020 | $174.67 | 5 | Astellas Pharma US Inc ($98.95) |
| 2019 | $259.21 | 6 | Sirtex Medical Inc ($122.98) |
| 2018 | $11.41 | 1 | Novocure Inc. ($11.41) |
| 2017 | $29.40 | 2 | Celgene Corporation ($18.58) |
All Payment Transactions
18 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/05/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Education | In-kind items and services | $18.09 | General |
| Category: ONCOLOGY | ||||||
| 04/10/2023 | PFIZER INC. | XTANDI (Drug) | Education | In-kind items and services | $13.86 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 04/13/2021 | Acrotech Biopharma LLC | BELEODAQ (Drug) | Education | In-kind items and services | $11.97 | General |
| Category: ONCOLOGY | ||||||
| 11/17/2020 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Education | In-kind items and services | $12.45 | General |
| Category: Oncology | ||||||
| 08/17/2020 | Astellas Pharma US Inc | — | Education | In-kind items and services | $98.95 | General |
| 08/17/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | Cash or cash equivalent | $17.33 | General |
| Category: Oncology | ||||||
| 05/06/2020 | Welch Allyn | None (Device) | Gift | In-kind items and services | $33.70 | General |
| Category: Not Applicable | ||||||
| 03/12/2020 | PFIZER INC. | RUXIENCE (Biological) | Food and Beverage | In-kind items and services | $12.24 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $13.69 | General |
| Category: ONCOLOGY | ||||||
| 10/02/2019 | Sirtex Medical Inc | SIR-Spheres Microspheres (Device) | Food and Beverage | Cash or cash equivalent | $122.98 | General |
| Category: Interventional Oncology | ||||||
| 07/12/2019 | PFIZER INC. | MYLOTARG (Biological), DAURISMO | Food and Beverage | In-kind items and services | $12.31 | General |
| Category: ONCOLOGY | ||||||
| 06/02/2019 | Elekta, Inc. | Versa HD (Device), Mosaiq, Esteya | Food and Beverage | Cash or cash equivalent | $91.36 | General |
| Category: ELEKTA LINEAR ACCELERATOR | ||||||
| 02/15/2019 | Clovis Oncology, Inc. | Rubraca (Drug) | Food and Beverage | In-kind items and services | $7.04 | General |
| Category: Oncology | ||||||
| 02/13/2019 | PFIZER INC. | DAURISMO (Drug) | Food and Beverage | In-kind items and services | $11.83 | General |
| Category: ONCOLOGY | ||||||
| 05/08/2018 | Novocure Inc. | Oncology (Device) | Food and Beverage | Cash or cash equivalent | $11.41 | General |
| Category: Optune | ||||||
| 06/01/2017 | Celgene Corporation | Revlimid (Drug) | Food and Beverage | In-kind items and services | $18.58 | General |
| Category: Hematology / Oncology | ||||||
| 03/23/2017 | Merck Sharp & Dohme Corporation | EMEND (Drug), KEYTRUDA | Food and Beverage | In-kind items and services | $10.82 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 114 | 6,604 | 449,020 | $17.5M | $6.3M |
| 2022 | 110 | 6,650 | 457,366 | $17.0M | $6.1M |
| 2021 | 118 | 7,172 | 418,126 | $16.9M | $6.1M |
| 2020 | 111 | 6,281 | 338,215 | $12.1M | $4.3M |
Total Patients
26,707
Total Services
1,662,727
Medicare Billing
$22.7M
Procedure Codes
453
All Medicare Procedures & Services
453 procedure records from CMS Medicare Utilization — Page 1 of 19
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 39 | 54,213 | $3.0M | $1.3M | 43.0% |
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 48 | 28,405 | $2.7M | $1.2M | 45.1% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 28 | 24,120 | $2.1M | $915,059 | 44.6% |
| J9022 | Injection, atezolizumab, 10 mg | Office | 2023 | 16 | 6,552 | $930,384 | $419,208 | 45.1% |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 48 | 10,620 | $945,180 | $403,419 | 42.7% |
| J1930 | Injection, lanreotide, 1 mg | Office | 2023 | 20 | 9,120 | $1.1M | $397,529 | 35.7% |
| J9173 | Injection, durvalumab, 10 mg | Office | 2023 | 14 | 4,968 | $685,584 | $308,663 | 45.0% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 65 | 11,100 | $466,200 | $200,123 | 42.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 296 | 1,143 | $412,623 | $113,680 | 27.6% |
| J1449 | Injection, eflapegrastim-xnst, 0.1 mg | Office | 2023 | 15 | 3,696 | $318,912 | $95,035 | 29.8% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 42 | 37,370 | $371,370 | $86,508 | 23.3% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 27 | 846 | $267,960 | $71,222 | 26.6% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 83 | 81,750 | $327,000 | $70,518 | 21.6% |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 2023 | 18 | 2,299 | $302,746 | $53,635 | 17.7% |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | Office | 2023 | 17 | 444 | $245,064 | $48,613 | 19.8% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 102 | 36,140 | $289,120 | $47,643 | 16.5% |
| J9305 | Injection, pemetrexed, not otherwise specified, 10 mg | Office | 2023 | 20 | 4,648 | $455,416 | $45,834 | 10.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 284 | 479 | $105,380 | $45,323 | 43.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 445 | 565 | $83,620 | $35,711 | 42.7% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 46 | 170 | $115,648 | $34,560 | 29.9% |
| Q5116 | Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg | Office | 2023 | 11 | 1,313 | $114,231 | $26,623 | 23.3% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 232 | 2,033 | $121,980 | $23,963 | 19.6% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 69 | 418 | $84,018 | $23,175 | 27.6% |
| J9041 | Injection, bortezomib, 0.1 mg | Office | 2023 | 25 | 4,935 | $366,415 | $19,697 | 5.4% |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | Office | 2023 | 12 | 216 | $82,080 | $18,953 | 23.1% |
About Dr. Richard Cherny, M.D
Dr. Richard Cherny, M.D is a Hematology & Oncology healthcare provider based in East Syracuse, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1659351484.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Richard Cherny, M.D has received a total of $530.53 in payments from pharmaceutical and medical device companies, with $18.09 received in 2024. These payments were reported across 18 transactions from 13 companies. The most common payment nature is "Food and Beverage" ($312.26).
As a Medicare-enrolled provider, Cherny has provided services to 26,707 Medicare beneficiaries, totaling 1,662,727 services with total Medicare billing of $22.7M. Data is available for 4 years (2020–2023), covering 453 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location East Syracuse, NY
- Active Since 01/18/2006
- Last Updated 08/03/2018
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1659351484
Products in Payments
- SIR-Spheres Microspheres (Device) $122.98
- Versa HD (Device) $91.36
- None (Device) $33.70
- KEYTRUDA (Biological) $31.78
- Revlimid (Drug) $18.58
- OPDIVO (Biological) $17.33
- XTANDI (Drug) $13.86
- XPOVIO (Drug) $12.45
- MYLOTARG (Biological) $12.31
- RUXIENCE (Biological) $12.24
- BELEODAQ (Drug) $11.97
- DAURISMO (Drug) $11.83
- Oncology (Device) $11.41
- EMEND (Drug) $10.82
- Rubraca (Drug) $7.04
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in East Syracuse
Santosh Kumar, Md, MD
Hematology & Oncology — Payments: $31,857
Hematology & Oncology $31,857
Vinod Varki, M.d, M.D
Hematology & Oncology — Payments: $14,348
Hematology & Oncology $14,348
Dr. Tarek Sousou, Md, MD
Hematology & Oncology — Payments: $3,099
Hematology & Oncology $3,099
Santo Difino, M.d, M.D
Hematology & Oncology — Payments: $1,159
Hematology & Oncology $1,159
Benny Wong, M.d, M.D
Hematology & Oncology — Payments: $1,083
Hematology & Oncology $1,083
Aref Agheli, Md, MD
Hematology & Oncology — Payments: $666.07
Hematology & Oncology $666.07